A Phase IIa Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multi-Center, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RWJ-445380 Administered to Patients With Plaque Psoriasis.
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2011
At a glance
- Drugs RWJ 445380 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Biomarker
- 27 Apr 2010 New trial record